Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

Summary

The primary objective of the study is to evaluate the efficacy of T-817MA in AD patients to treat dementia. Efficacy will be cognitive function, as measured by the ADAS-cog cognitive assessment. The secondary objectives of the study are to evaluate the safety of T-817MA and the activities of daily living (assessed with the ADCS-ADL) of AD patients taking T-817MA, and to evaluate the efficacy of T-817MA in AD patients with an overall global assessment using the ADCS-CGIC.

Timeline

Start

2008-04

Primary completion

2011-05

Completion

2011-06

Drugs

Indications